123 related articles for article (PubMed ID: 7036277)
21. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
[TBL] [Abstract][Full Text] [Related]
22. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
Gottwald G; Szakolczai I
Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
[No Abstract] [Full Text] [Related]
23. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
24. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant combination chemotherapy with CMF in primary mammary carcinoma.
Veronesi U; Rossi A; Bonadonna G
World J Surg; 1977 May; 1(3):337-40. PubMed ID: 883333
[No Abstract] [Full Text] [Related]
26. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
[TBL] [Abstract][Full Text] [Related]
27. Dose-response effect of adjuvant chemotherapy in breast cancer.
Bonadonna G; Valagussa P
N Engl J Med; 1981 Jan; 304(1):10-5. PubMed ID: 7432433
[TBL] [Abstract][Full Text] [Related]
28. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
[TBL] [Abstract][Full Text] [Related]
29. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
30. Multimodal therapy for histological stage-II breast cancer. Multicentre Breast Cancer Chemotherapy Group.
Lancet; 1977 Aug; 2(8034):396-7. PubMed ID: 70600
[No Abstract] [Full Text] [Related]
31. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles].
Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G
Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814
[No Abstract] [Full Text] [Related]
33. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
34. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
Bonadonna G; Zambetti M; Valagussa P
JAMA; 1995 Feb; 273(7):542-7. PubMed ID: 7837388
[TBL] [Abstract][Full Text] [Related]
35. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
37. Surgical adjuvant trials in the United States.
Rozencweig M; Von Hoff DD; Allegra JC; Muggia FM
Eur J Cancer (1965); 1980; Suppl 1():173-7. PubMed ID: 7032929
[No Abstract] [Full Text] [Related]
38. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.
Rubens RD; Knight RK; Hayward JL
Br J Cancer; 1975 Dec; 32(6):730-6. PubMed ID: 766800
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK
Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926
[No Abstract] [Full Text] [Related]
40. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]